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Enterococci are increasingly recognized as important noso-
comial pathogens. Studies in children have shown that neonates
and compromised hosts are especially at risk; that bacteremia
and sepsis were the most prominent manifestations of infection;
that enterococcal bacteremia occurred often in the setting of
polymicrobial infections and that the attributable mortality was
about 20–25% [1–4]. In the present study risk factors for colon-
ization with enterococci in newborns are described. A retro-
spective case-control study on risk factors for colonization with
enterococci was performed in the neonatal intensive care unit
(NICU) of the Beatrix Children’s Hospital, Groningen, The
Netherlands. All newborns admitted to the unit from 1 January
1994 until 31 December 1994 were included. Fecal and throat
cultures were taken on admission and twice weekly afterwards.
Infants were considered colonized when enterococci were iso-
lated on esculin plates (Merck, Darmstadt, Germany) at least
once from throat or faeces. Only faeces cultures in which
enterococci were predominant were considered positive. Con-
trols were a random selection of the newborns admitted during
the study period and not colonized with enterococci during
their stay in the NICU. Resistance to vancomycin was not
determined in this study, since it is still a very rare event in the
Netherlands [5].
Between 1 January 1994 and 31 December 1994, a total of
579 newborns were admitted of which 116 (20%) were colon-
ized with enterococci. The site of colonization was the faeces
in 54 patients, the throat in 51 patients and both faeces and
throat in 11 patients. In an univariate analysis of possible risk
factors for colonization with enterococci a shorter gestational
age (P  0.001), a lower birth weight (P = 0.02), an increased
number of days of hospitalization, mechanical ventilation, treat-
ment via a central venous line, parenteral nutrition and anti-
biotic use (all P  0.001) were associated with enterococcal
colonization. Major surgery and episodes of clinical features
compatible with infection were also risk factors (P  0.001).
Multiple regression analysis showed that a longer gestational
age [odds ratio(OR), 2.12; 95% confidence interval (CI), 1.04–
4.34], a longer duration of hospitalization (OR, 1.07; 95% CI,
1.04–1.09), the use of antibiotics other than amoxicillin (OR,
3.32; 95% CI, 1.30–8.50) and the use of a central venous line
(OR, 2.51; 95% CI, 1.12–5.63) were the only independent risk
factors (Table 1).
© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 53
Table 1 Multiple regression analysis of risk factors for
colonization with enterococci
OR 95% CI P
Gestational age 37 weeks 2.12 1.04–4.34 0.039
Days of hospitalization 1.07 1.04–1.09 0.001
Deep venous line in place 2.51 1.12–5.63 0.026
Antibiotics other than amoxicillin 3.32 1.30–8.50 0.013
OR, odds ratio; CI, confidence interval.
Neonates with these risk factors should be monitored closely
for the development of enterococcal bacteremia and sepsis.
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Cutaneous sporotrichosis: the old iodide treatment remains
effective
Clin Microbiol Infect 2000: 6: 53–55
Sporotrichosis, a common disease in the Midwestern river val-
leys of the United States and rare in the state of Michigan,
clinically mimics other diseases that are frequently associated
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with the occupation of patients, such as mycobacteriosis,
cryptococcosis, woolsorters’ disease, cat scratch disease and
nocardiosis. A strong clinical suspicion may be confirmed by
isolation of the organism. Treatment of sporotrichosis can be
difficult, mainly due to patient compliance over the long dur-
ation of treatment. In addition, the treatment is expensive,
especially with use of the new antifungal drugs, although these
are better reserved for systemic forms of the infection. The
cutaneous form of the disease can be treated in the ‘old’ way,
with a saturated solution of potassium iodide (SSKI), which is
inexpensive. We present such a case to emphasize the usefulness
of such therapy.
Eight months prior to his referral to a county free clinic, a
40-year-old man had cut his left index finger near the knuckle
while working in a garden. He had always worked in jobs such
as yard work or swimming pool cleaning that exposed him to
soil or water. The lesion became erythematous and nodular and
later formed crusts without purulent discharge. After 2 to 3
months, he noticed an increasing number of similar lesions
proximally on the lateral and dorsal aspect of the upper
extremity, reaching the lower part of his arm. The sizes of the
lesions increased to about 2 cm in diameter and in the few
weeks prior to his visit to the clinic, these lesions were more
nodular and tender. He had no itching, no fever, no chills, no
arthralgia nor joint swelling, and no cough.
On examination, the patient was a well-built, healthy man.
His temperature was 37.3 °C, pulse was 80/min. and respiratory
rate 16/min. With the exception of the skin lesions, the physical
examination was essentially within normal limits. On the left
upper extremity he had multiple lesions 1.5 to 2 cm in size
with central excoriation and erythematous border. He also had
several smaller, slightly tender erythematous nodules. These
were present from the original lesion at the left index finger to
the lower arm, as shown in Figure 1. He had no lymphad-
enopathy.
Figure 1 Lesions from cutaneous sporotrichosis appearing at
left index finger to lower arm on initial visit.
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Laboratory investigations yielded the following: white blood
count (WBC) was 9300, hemoglobin 16.2 gm%, hematocrit
47.2%, platelet 342 000 with normal differential count; eryth-
rocyte sedimentation rate (ESR) was 5 mm in the first hour. The
chest X-ray was normal. A direct microbiological examination
from two lesions was negative for fungus, but the culture
showed moderate growth of Sporothrix schenckii. Smear and
culture tests for mycobacteria were negative.
The patient was followed at our Infectious Disease Clinic.
After we diagnosed cutaneous sporotrichosis, he was treated
with SSKI. The initial dose level was 0.5 mL, taken three times
a day, and this dose level was increase by 0.5 mL per day until
it reached 4 mL, taken three times a day. He took the SSKI
mixed in juice. After 1 month, there was significant improve-
ment—the lesions had decreased in size by at least 50%; there
was no crust and hardly any nodular lesions. His last visit was
8 weeks after initiation of therapy. By this time, he had taken
SSKI for nearly 7 weeks (he interrupted treatment for 10 days
because of a minor side-effect – bitter taste). Figure 2 reveals
the healing of all lesions. He had suffered no relapse at follow-
up, 8 months after SSKI was discontinued.
Cutaneous/lymphocutaneous sporotrichosis, a mycotic
infection, has a chronic course and usually affects individuals
who are exposed to soil or other environmental or plant (thorns
or wood) sources that may lead to traumatic inoculation of the
causative agent Sporothrix schenckii. Among other conditions to
be considered on the differential diagnosis are mycobacteriosis,
cryptococcosis, blastomycosis, cutaneous anthrax, nocardiosis
and bacillary angiomatosis or pyogenic infections. The clinical
diagnosis can be confirmed by the isolation of the organism as
in the case presented.
Standard treatment of sporotrichosis is by using antifungal
drugs for an extended period of time. SSKI had been the drug
of choice for this form of sporotrichosis since the early part of
this century. More recently, the azole antifungal agents have
Figure 2 All lesions healed 8 weeks after SSKI therapy. The
patient had no relapse after 8 months.
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superseded the use of SSKI. Some of the side-effects—such as
bitter metallic taste, nausea, rash and anorexia—have been the
reason for limited use, but it remains an inexpensive therapy in
developing countries. We elected to treat our patient, who was
first seen in a free clinic, with SSKI, an effective and inexpensive
drug, rather than using the newer, costly azole antifungal drugs.
There has been dramatic improvement in the lesions as shown
in Figure 2. The drawback of the drug is the adverse effect that
occurred in this patient several weeks after he started treatment.
We emphasize that in this era of cost containment, the use
of SSKI is an inexpensive and effective treatment for cutaneous/
lymphocutaneous sporotrichosis.
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Successful treatment of Actinobacillus actinomycetemcomitans
endocarditis with ofloxacin
Clin Microbiol Infect 2000: 6: 55–56
Endocarditis due to HACEK organisms (Haemophilus sp., Acti-
nobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella
corrodens, Kingella kingae) are usually treated with ampicillin or
ceftriaxone plus an aminoglycoside for 4 weeks. That treatment
can be difficult to achieve in patients with poor venous access
or in cases of allergy to b-lactam antibiotics. Fluoroquinolones
are antibiotics characterized by an excellent oral bioavailability
and a high diffusion in tissue and cardiac vegetations [1]. Thus,
they could be an interesting alternative to the b-lactam-ami-
noglycoside treatment. To our knowledge, only one case of
A. actinomycetemcommitans (Aa) endocarditis being successfully
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treated by fluoroquinolone has yet been reported [2]. We pre-
sent here a second case.
A 65-year-old man was admitted to the Infectious Disease
Department on January 1998. He had been suffering for 30 years
with mitral regurgitation complicating a mitral valve prolapse.
During the past 3 months, he presented with three febrile
episodes, each of which was rapidly resolved after an oral anti-
biotic treatment given by his family doctor. Successive echo-
cardiographic examinations performed by his cardiologist,
including a transoesophageal echocardiography, showed a
recent worsening of the mitral regurgitation (grade 3–4), with-
out vegetations.
On admission, he was febrile (38.2 °C). The physical exam-
ination found only the known mitral regurgitation murmur.
There was no sign of cardiac failure. Urine-analysis was normal.
Inflammatory parameters values were: ESR, 122 mm; C-reac-
tive protein (CRP), 122 mg/L. Three of six blood cultures
were positive for Aa. The rod was sensitive to: ampicillin,
third-generation cephalosporins, macrolides, tetracyclines,
aminoglycosides and fluoroquinolones (ofloxacin and
ciprofloxacin). Dental examination revealed the presence of an
infectious focus on tooth 47. Aa endocarditis was diagnosed.
Initial treatment was with amoxicillin and netilmicin. The
patient became afebrile on day 5 of treatment. On day 8,
intravenous treatment was rendered impossible due to insuf-
ficient peripheral venous access. Ofloxacin oral treatment at a
dosage of 200 mg three times daily was initiated. At this time,
the ESR was 120 mm and CRP, 47 mg/L. Ofloxacin MIC
against Aa was 0.03 mg/L by E-test. Fifteen days after the
beginning of ofloxacin treatment, peak serum concentration of
ofloxacin was 8.3 mg/L using high-performance liquid chro-
matography (Dr Jehl, Institut de Bacte´riologie, Strasbourg,
France).
The duration of ofloxacin treatment was 5 weeks. Apyrexia
persisted throughout the antibiotic treatment and inflammatory
parameters returned to normal values. A new echocardiograph
at the end of treatment confirmed the absence of vegetations
or further worsening of mitral regurgitation. One year later,
the patient remained free of clinical or biological signs of relapse.
In 1995, Babinchak reported a case of mitral prosthetic valve
Aa endocarditis successfully treated by ciprofloxacin (750 mg,
twice daily) [2]. The patient had no vegetations or cardiac
failure. The outcome was favorable. The minimum inhibitory
concentration (MIC) of ciprofloxacin against the rod was
0.019 mg/L. The serum level of ciprofloxacin at the steady state
was 4.1 mg/L 6 h after the intake of 750 mg, which cor-
responded to approximately 200-fold the MIC of ciprofloxacin.
We report a second case involving native mitral valve, in which
ofloxacin, given at high dosage, permitted achievement of
a peak serum level of more than 200-fold the MIC against
Aa.
In experimental models of endocarditis, the bactericidal
